Sign in

CIK 0001287098

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

MAXCYTE, INC.

Sign in to watch
Ticker
MXCT
Exchange
Nasdaq
Industry
Services-Commercial Physical & Biological Research
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
522210438
Phone
+1 301-517-5556
Business address
9713 KEY WEST AVENUE,, SUITE 400, ROCKVILLE, MD, 20850
Former names
MAXCYTE INC
  1. 4 Grant or award Director acquired 29,210 shares (grant or award)
  2. 4 Grant or award Director acquired 29,210 shares (grant or award)
  3. 4 Grant or award Director acquired 29,210 shares (grant or award)
  4. 4 Grant or award Director acquired 29,210 shares (grant or award)
  5. 4 Grant or award Director acquired 29,210 shares (grant or award)
  6. 4 Grant or award Director acquired 29,210 shares (grant or award)
  7. 4 Grant or award Director acquired 29,210 shares (grant or award)
  8. 4 Open-market sale Chief Commercial Officer sold 1,211 shares at $3.18 ($3,850)
  9. 4 Open-market sale GENERAL COUNSEL sold 353 shares at $3.18 ($1,122)
  10. 4 Open-market sale CHIEF FINANCIAL OFFICER sold 6,939 shares at $3.18 ($22,061)
  11. 4 Grant or award Chief Commercial Officer acquired 34,625 shares (grant or award)
  12. 4 Grant or award GENERAL COUNSEL acquired 23,125 shares (grant or award)
  13. 4 Grant or award CHIEF FINANCIAL OFFICER acquired 37,500 shares (grant or award)
  14. 4 Derivatives Options or other derivatives
  15. 4 Planned sale Director sold 3,000 shares at $4.65 ($13,935)
  16. 4 Open-market sale GENERAL COUNSEL sold 4,466 shares at $4.54 ($20,272)
  17. 4 Planned sale Director sold 3,000 shares at $4.01 ($12,021)
  18. 4 Planned sale Director sold 3,000 shares at an average $3.78 ($11,328)
  19. 4 Planned sale Director sold 47,689 shares at $3.72 ($177,403)
  20. 4 Planned sale Director sold 3,000 shares at $3.72 ($11,166)

Page 2 of 9 · 163 filings